ABT - Abbott Laboratories

NYSE - Nasdaq Real Time Price. Currency in USD
62.405
+0.565 (+0.91%)
As of 2:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close61.840
Open61.890
Bid62.520 x 900
Ask62.520 x 800
Day's Range61.900 - 62.710
52 Week Range43.440 - 64.600
Volume3,409,192
Avg. Volume6,287,212
Market Cap109.408B
Beta1.67
PE Ratio (TTM)231.99
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.12 (1.88%)
Ex-Dividend Date2018-04-12
1y Target EstN/A
Trade prices are not sourced from all markets
  • Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
    Zacks5 hours ago

    Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing

    Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.

  • The Performance of Roche’s Diagnostics Division in Q1 2018
    Market Realist3 days ago

    The Performance of Roche’s Diagnostics Division in Q1 2018

    Roche’s (RHHBY) Diagnostics division comprises tissue diagnostics, molecular diagnostics, diabetes care, and centralized and point-of-care solutions. Roche’s Diagnostics division grew 5.0% year-over-year to reach ~2.9 billion Swiss francs.

  • Shocking the Spine Offers an Alternative to Opioids
    Bloomberg3 days ago

    Shocking the Spine Offers an Alternative to Opioids

    Like millions of people caught up in America’s opioid crisis, Rick Surkin used to take a pill just to get out of bed in the morning. Until last year, the former firefighter relied on thrice-daily doses of the powerful painkiller OxyContin to numb the agony from a ruptured disc in his back. The series of tiny shocks, known as neuromodulation, has kept Surkin comfortable enough to ditch Oxy.

  • Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?
    Zacks6 days ago

    Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?

    Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • How Did Bausch + Lomb Perform in 1Q18?
    Market Realist9 days ago

    How Did Bausch + Lomb Perform in 1Q18?

    In 1Q18, Valeant Pharmaceuticals’ (VRX) subsidiary, Bausch + Lomb, generated revenues of $1.10 billion compared to $1.13 billion in 1Q17, which reflected an ~3.0% decline on a year-over-year (or YoY) basis. In 1Q18, Bausch + Lomb witnessed 2.0% organic growth compared to 1Q17.

  • Will Abbott Laboratories (NYSE:ABT) Continue To Underperform Its Industry?
    Simply Wall St.10 days ago

    Will Abbott Laboratories (NYSE:ABT) Continue To Underperform Its Industry?

    Abbott Laboratories (NYSE:ABT) generated a below-average return on equity of 1.19% in the past 12 months, while its industry returned 10.98%. ABT’s results could indicate a relatively inefficient operation toRead More...

  • The Wall Street Journal13 days ago

    [$$] Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study

    An increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications, a new study found. The outcome of the trial raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. make the device used in the procedure.

  • A Overview of Merck’s Diabetes Products in 1Q18
    Market Realist15 days ago

    A Overview of Merck’s Diabetes Products in 1Q18

    Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.

  • How Analysts View Allergan after Its 1Q18 Earnings
    Market Realist16 days ago

    How Analysts View Allergan after Its 1Q18 Earnings

    Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.

  • A Look at Abbott Laboratories’ Valuation Multiples
    Market Realist16 days ago

    A Look at Abbott Laboratories’ Valuation Multiples

    On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.

  • Is It Time To Buy Abbott Laboratories (NYSE:ABT)?
    Simply Wall St.17 days ago

    Is It Time To Buy Abbott Laboratories (NYSE:ABT)?

    Today we’re going to take a look at the well-established Abbott Laboratories (NYSE:ABT). The company’s stock received a lot of attention from a substantial price movement on the NYSE overRead More...

  • A Brief Look at Abbott’s Alere Integration Progress and Recovery
    Market Realist17 days ago

    A Brief Look at Abbott’s Alere Integration Progress and Recovery

    (Continued from Prior Part)Alere acquisition integration progress Abbott Laboratories (ABT) completed its acquisition of Alere in October 2017. The company has experienced significant difficulties with the acquisition over the past year. Let’s take a look at how the acquisition has progressed. According to Abbott Laboratories, the bulk of the integration work is complete, and the company has established strategies and plans for the Alere business.  The company added that the Alere acquisition’s synergies are on track, and the company seems to have benefited from the deal. ...

  • Discussing Abbott’s Market Position and Growth Prospects in China
    Market Realist17 days ago

    Discussing Abbott’s Market Position and Growth Prospects in China

    Abbott Laboratories (ABT) has registered some pressure in its China Nutritionals business. Over the past year, the market has seen trends such as oversupply leading to price discounting due to new food safety regulations that should become effective in 2018. Since the new food safety regulations have come into effect starting January 1, China’s nutrition market has seen improving market conditions.

  • Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?
    Market Realist17 days ago

    Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?

    In 1Q18, Abbott Laboratories (ABT) reported sales of $535.0 million in its CRM (Cardiac Rhythm Management) business, which contributed ~19.5% to the company’s total sales of $2.7 billion in the quarter. The segment’s sales, however, registered flat YoY (year-over-year) growth on an organic basis. Abbott’s Cardiovascular segment—consisting of its Rhythm Management, Electrophysiology, Heart Failure, Structural Heart, and Vascular businesses—reported sales of $2.1 billion in 1Q18.

  • Forbes20 days ago

    Despite Youth On Farm, Abbott Ventures Chief Avoids Spreading Manure

    Abbott Ventures chief Evan Norton may have spent part of his youth on a farm, but there’s no manure in his manner when speaking of the medical device and diagnostics market landscape. The key, he says, is to avoid being blindsided by the transformational power of digital data. “We’ve been competing against Medtronic and J&J, so that has the risk of us being disintermediated by other players that come into the market,” Norton told attendees at MedCity Invest, a meeting focused on health care entrepreneurs.

  • Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects
    Market Realist20 days ago

    Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

    Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.

  • New Product Launches Drive ABT’s Medical Device Business
    Market Realist20 days ago

    New Product Launches Drive ABT’s Medical Device Business

    (Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments.  ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...

  • ABT’s Medical Devices Business: A Key Growth Driver
    Market Realist20 days ago

    ABT’s Medical Devices Business: A Key Growth Driver

    On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates. 

  • ABT’s Recent Stock Slump: What’s behind the Decline?
    Market Realist21 days ago

    ABT’s Recent Stock Slump: What’s behind the Decline?

    On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.

  • Abbott Laboratories’ Strong Organic Growth Momentum in 1Q18
    Market Realist21 days ago

    Abbott Laboratories’ Strong Organic Growth Momentum in 1Q18

    In 1Q18, Abbott Laboratories (ABT) registered organic sales growth of ~6.9%, which came in at the high end of the company’s guidance range of 6.0%–7.0%. The company’s Nutrition segment is also picking up momentum while its Pharmaceuticals business was weaker than expected. The company, however, is confident of the sustainable growth going forward, boosted by recent launches and approvals.

  • Analysts’ Recent Recommendations and Target Price for ABT Stock
    Market Realist21 days ago

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.